Merck & Co., Inc. (NYSE:MRK) Sets New 12-Month High – Time to Buy?

Shares of Merck & Co., Inc. (NYSE:MRK) reached a new 52-week high during trading on Thursday . The company traded as high as $125.36 and last traded at $125.5010, with a volume of 6550201 shares. The stock had previously closed at $120.60.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The European Commission approved Keytruda plus Padcev for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, expanding Merck’s oncology footprint in Europe and adding another label expansion for a major growth drug. European Commission Approves KEYTRUDA Plus Padcev
• Positive Sentiment: The U.S. FDA also approved Keytruda and Keytruda Qlex in combination with Gilead’s Trodelvy for first-line treatment of PD-L1+ advanced triple-negative breast cancer, reinforcing Merck’s ability to keep extending Keytruda into new cancer settings. FDA Approves KEYTRUDA and KEYTRUDA QLEX with Trodelvy
• Positive Sentiment: Merck’s experimental tulisokibart also hit its goal in a late-stage ulcerative colitis study, helping investors see progress beyond Keytruda and strengthening the company’s immunology pipeline. Merck’s Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
• Positive Sentiment: Analyst coverage has been constructive, with CICC Research initiating coverage with an outperform rating and a $138 price target, suggesting additional upside from current levels. CICC Research coverage note
• Neutral Sentiment: Other recent analyst notes were mixed, with Citi reiterating Hold and Scotiabank reaffirming Buy, which adds commentary but does not materially change the main investment story. Citi keeps hold rating Scotiabank reaffirms buy rating

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MRK shares. JPMorgan Chase & Co. raised their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research note on Monday, April 6th. CICC Research initiated coverage on Merck & Co., Inc. in a research note on Wednesday. They set an “outperform” rating and a $138.00 target price on the stock. Wells Fargo & Company reduced their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Citigroup began coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective for the company. Finally, Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $128.72.

Merck & Co., Inc. Stock Up 4.3%

The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock has a market cap of $310.64 billion, a PE ratio of 35.43, a price-to-earnings-growth ratio of 2.69 and a beta of 0.21. The business has a fifty day moving average of $115.77 and a 200-day moving average of $114.05.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period last year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. in the fourth quarter worth approximately $25,000. Prosperity Bancshares Inc purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $26,000. Abound Financial LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $26,000. IFC & Insurance Marketing Inc. bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth $31,000. Finally, High Note Wealth LLC lifted its stake in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.